Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek February 6, 2006 Emily Thornton	More Heat On Hedge Funds As if there weren't enough controversy surrounding hedge funds, now the Securities & Exchange Commission is investigating suspicions that fund employees are engaging in insider trading.
Registered Rep. December 4, 2012 Megan Leonhardt	Blotter: December 2012 A former hedge fund manager for SAC Capital Advisors was arrested and charged with orchestrating a $276 million insider-trading scheme.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
The Motley Fool September 30, 2009 Brian Orelli	More Questions Than Answers From Elan Things that make you go hmmm.
BusinessWeek December 27, 2004 Emily Thornton	Hedge Funds Find An Escape Hatch The loophole: Locked-up funds don't require oversight. That means more risk for investors.
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
The Motley Fool March 3, 2010 Brian Orelli	A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%.
BusinessWeek October 21, 2009 Farzad & Francis	The SEC's Tough New Offensive on Insider Trading It's using wiretaps, informants, and high-tech software, as well as teaming with key federal prosecutors, to nab wrongdoers fast.
BusinessWeek March 12, 2007 Matthew Goldstein	Homing In On Trading Abuses Do allegations that a UBS worker sold info to hedge funds signal a growing problem?
The Motley Fool May 1, 2009 Brian Orelli	Catch the Perps Already Biotech may be the sector most susceptible to insider trading because there are so many binary events that can drastically change the stock price of a company in a very short time frame.
The Motley Fool July 10, 2006 Brian Lawler	Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced.
BusinessWeek May 11, 2011 Barrett et al.	The Rajaratnam Conviction: How Big a Victory? Raj Rajaratnam's conviction is the biggest blow against insider trading in a generation. Unfortunately, the Galleon case shows the problem is worse than ever.
The Motley Fool December 18, 2010 Gabriel Perna	iPhone, iPad Details Leaked by Man Charged With Insider Trading One of the four men arrested for taking part in an insider-trading scheme at several major technology firms leaked confidential details of Apple's new line of iPhones and iPads to hedge fund companies.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
BusinessWeek July 17, 2006 Mara Der Hovanesian	The SEC Isn't Finished With Hedge Funds The SEC is closing in on shady practices despite a setback from a federal court.
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
U.S. Banker September 2007 Lee Conrad	Oversight: Hedge Fund Transparency At Issue...Again The Securities & Exchange Commission is attempting to shine a spotlight on the most opaque of investments-hedge funds-by creating a working group in its enforcement division to combat insider trading.
CFO May 1, 2008 Alix Stuart	All in the Families The SEC is aiming to sniff out improper relationships, including insider trading, between hedge funds and the companies they invest in.
Registered Rep. December 2, 2003 Will Leitch	Spitzer, OCC Issue Corporate Death Penalty The news came right before the Thanksgiving holiday, so you might have missed it. But let there be no doubt: The mutual fund investigations have now gone nuclear.
The Motley Fool April 21, 2006 Stephen D. Simpson	Wily Wyeth For the most part, this business will produce high-single-digit revenue growth, and hopefully low-teens growth in earnings and cash flow. That means investors should be a little conservative buying in, but patient when holding.
The Motley Fool October 24, 2008 Brian Orelli	Elan's Approaching the Black Elan doesn't have positive cash flow yet, but it's getting closer, with revenue and expenses headed in the right direction.
The Motley Fool December 31, 2011 Brian Orelli	3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch.
On Wall Street July 1, 2009 Mark Astarita	The SEC's "Feel Good" Committee The Securities and Exchange Commission announces the formation of an Investor Advisory Committee, which it says will give investors a greater voice in its work.
The Motley Fool October 31, 2006 Brian Lawler	A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware.
The Motley Fool July 29, 2009 Brian Orelli	Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them.
The Motley Fool March 10, 2004 Selena Maranjian	Barring Bad Board Directors The SEC is cracking down, but enforcement is a problem.
BusinessWeek July 26, 2004 Paula Dwyer	The SEC To Top Execs: Read The Fine Print The Ken Lay criminal indictment has overshadowed the parallel SEC civil lawsuit. But corporate insiders and their attorneys would be wise to give the SEC complaint a close read.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
Financial Advisor February 2007 Thomas M. Kostigen	Firm Offers Reps Their Own Hedge Funds Independent broker-dealer First Allied's program raises questions about risk and conflicts.
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
Wall Street & Technology September 18, 2006	Registration's Lingering Effects It appears as though the ill-fated SEC hedge fund registration requirement will have a lasting effect on many in the hedge fund industry.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
Investment Advisor July 2008 Melanie Waddell	SEC Chairmen of Yore Speak Six former SEC chairmen pointed to quite a few regulatory challenges that loom large -- namely globalization of the world markets, the burgeoning market for complex synthetic securities, and the continued growth of hedge funds.
Fast Company February 2009 Elizabeth Svoboda	Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits.
The Motley Fool February 9, 2011 Brian Orelli	Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years.
The Motley Fool May 4, 2010 Brian Orelli	Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank?
BusinessWeek October 6, 2003 Stephen B. Shepard	Straight Talk from Eliot Spitzer The New York Attorney General speaks on the mutual-fund investigations and other issues
Reason October 2003 Michael McMenamin	St. Martha Why Martha Stewart should go to heaven and the SEC should go to hell.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool July 15, 2004 Tim Beyers	SEC Hedges on Funds The Securities and Exchange Commission (SEC), in a hotly contested battle, chose to force more regulation on the fund industry. A new rule requires hedge funds to register.
BusinessWeek July 19, 2004 Borrus & Dwyer	Lobbying For Laissez-Faire Hedge funds are pouring money into campaign coffers in the U.S. to stop SEC regulation.
Registered Rep. May 10, 2007 Kristen French	SEC Impostors on the Loose The SEC issued an alert to securities industry firms, warning them to keep an eye out for impostors -- individuals pretending to work for the SEC.
Investment Advisor December 2006 Melanie Waddell	Democrats and Hedge Funds Will the new party in power turn up the regulatory heat? The SEC itself has gotten more vigilant and expanded its enforcement activities against hedge funds.
The Motley Fool May 2, 2007 Mike Havrilla	Heads Up, Biotech Investors: Chapter 2 Get to know the timing of major catalysts for stocks that may be on your biotech watch list.
HBS Working Knowledge October 6, 2003 D. Quinn Mills	The Problem with Hedge Funds Hedge funds are the New Big Thing -- and that's bad for the average investor, says professor D. Quinn Mills. An excerpt from Wheel, Deal, and Steal.
The Motley Fool July 31, 2008 Brian Lawler	Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it?
Wall Street & Technology January 5, 2005 Maria Santos	The Cost of Compliance The U.S. Securities and Exchange Commission has come under scrutiny again following the adoption of a recent rule regarding hedge funds.
Registered Rep. January 9, 2007 John Churchill	To Hedge Gets Harder The SEC proposed a rule in December that would raise the net worth requirements of investors in hedge funds to $2.5 million from $1 million, not including the value of one's home.
The Motley Fool November 21, 2008 Rich Duprey	Hedge Funds Ask: Where's the Love? It's been a long, strange trip since the hedge fund industry's summer-of-love confab.